#South Korea #Seoul #IPF #Bersiporocin #Daewoong Pharmaceutical

Overview of the Presentation

On September 6, 2026, at the European Respiratory Society (ERS) Congress 2026 held in Barcelona, Daewoong Pharmaceutical showcased significant research findings regarding their investigational drug 'Bersiporocin' (DWN12088) aimed at treating idiopathic pulmonary fibrosis (IPF). The poster presentation detailed the baseline characteristics of 104 participants enrolled in a global Phase 2 clinical trial designed to explore the drug's efficacy and safety.

Understanding Idiopathic Pulmonary Fibrosis (IPF)

IPF is a progressive disease characterized by an accumulation of scar tissue in the lungs, caused by various inflammatory and fibrotic signals. The excessive collagen production due to these signals leads to reduced lung function and, ultimately, respiratory failure. This condition poses significant challenges for patients and highlights the urgent need for effective treatment options.

The Role of Bersiporocin in the Treatment Landscape

Bersiporocin is a first-in-class prolyl-tRNA synthetase (PRS) inhibitor. Its unique mechanism of action specifically targets collagen synthesis that occurs downstream of multiple profibrotic signals, which is a significant advancement compared to existing treatments. The drug is evaluated in patients both on background antifibrotic therapy and those who are not, meaning it caters to a broad spectrum of IPF management scenarios.

Key Findings from the Clinical Trial

According to the data presented, out of the 104 patients enrolled in this international study, a majority were sourced from South Korea (55 participants or 52.9%) and the remaining 49 patients (47.1%) were recruited from the United States. Among these participants, 71 patients, which constitutes approximately 68.3%, were already undergoing treatment with background antifibrotic medication, while 33 patients (31.7%) were not.

The mean forced vital capacity (FVC) among these patients was around 77% of the predicted value, indicating a significant reduction in lung function, as expected in IPF, while the mean diffusing capacity of the lungs for carbon monoxide (DLCO) stood at about 51% predicted. Importantly, the analysis indicated that there were minimal differences in baseline clinical and functional characteristics between those receiving antifibrotic therapy and those who were not.

The Study's Design and Implications

The global Phase 2 trial is a randomized, double-blind, placebo-controlled study executed across South Korea and the US. Participants are assigned to receive either Bersiporocin or a placebo twice daily over a period of 24 weeks. Importantly, the study design mirrors real-life treatment settings as it includes both patients undergoing background therapy and those who are not, yielding valuable insights into the potential benefits of Bersiporocin across varied patient profiles.

This foundational analysis will be pivotal in contextualizing the Phase 2 efficacy and safety outcomes that are expected to be revealed in the first half of 2027. Moreover, Bersiporocin has already garnered Orphan Drug Designation and Fast Track status from the US FDA, as well as similar recognitions from the European Medicines Agency (EMA), emphasizing its potential in transforming the treatment landscape for IPF.

Expert Insights

Professor Moo Suk Park from the Department of Pulmonology at Severance Hospital, who contributed to this research, stated, "This study offers a comprehensive profile of the baseline characteristics of 104 IPF patients, including those receiving and not receiving background therapy. These data will provide crucial interpretative context for the forthcoming efficacy and safety evaluations of Bersiporocin in IPF treatment."

Daewoong Pharmaceutical's CEO, Seongsoo Park, also expressed optimism regarding the trial's progress, noting, "The completion of patient enrollment for this Phase 2 trial and the thorough representation of baseline characteristics at ERS 2026 marks a significant breakthrough in Bersiporocin's development journey. We remain committed to advancing this promising program towards the anticipated top-line results next year."

Conclusion

Daewoong Pharmaceutical's initiative with Bersiporocin underscores a pivotal moment in the exploration of new therapeutic options for IPF. As the clinical trial progresses, all eyes will be on the comprehensive data that emerges, which could very well shape the future of treatment for this challenging lung disorder.